Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation & Amortization (2021 - 2025)

Amylyx Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $1.6 million for Q4 2025, up 14.35% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 14.35% YoY), and the annual figure for FY2025 was $1.6 million, up 14.35%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $1.6 million at Amylyx Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for AMLX hit a ceiling of $1.6 million in Q4 2023 and a floor of $53000.0 in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $1.4 million (2024), compared with a mean of $1.0 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 918.87% in 2022 and later decreased 16.52% in 2024.
  • Amylyx Pharmaceuticals' Accumulated Depreciation & Amortization stood at $53000.0 in 2021, then soared by 918.87% to $540000.0 in 2022, then soared by 201.48% to $1.6 million in 2023, then fell by 16.52% to $1.4 million in 2024, then grew by 14.35% to $1.6 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $1.6 million (Q4 2025), $1.4 million (Q4 2024), and $1.6 million (Q4 2023) per Business Quant data.